Strides Pharma Share Price: Debt Kam, Toh Ab Global Expansion Ka Bada Plan!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorIshaan Verma|Published at:
Strides Pharma Share Price: Debt Kam, Toh Ab Global Expansion Ka Bada Plan!
Overview

Strides Pharma Science ek naye growth phase mein enter kar rahi hai! Company ne apna debt kaafi hadd tak kam kar diya hai, jiske baad woh ab **U.S.** ke alawa doosre markets mein, especially **Africa** mein, tezi se expand karne ka plan bana rahi hai.

Videshi Market Mein Dhamaka?

Arey, ye company ab videshi market mein dhamaka karne ke mood mein hai! Pichle kuch samay mein inhone apna debt almost half kar diya hai, aur ab net debt to EBITDA ratio 1.6x ho gaya hai (FY26 Q3 tak). Isse company ke paas ab paisa hai invest karne ke liye.

U.S. market still bahut strong hai, jahan se lagbhag 52% revenue aata hai FY26 mein. Lekin ab company U.S. ke bahar ke markets mein bhi tezi se growth dekh rahi hai, jaise UK, Europe, Australia, aur khaas kar Africa! Haal hi mein Africa mein Sandoz branded generics assets ki deal ki hai, jisse mid-50s million dollars ka revenue aur 14-15% CAGR expect hai.

U.S. mein bhi ab chronic therapies aur differentiated products par zyada focus rahega, aiming for $400 million revenue by 2028.

Balance Sheet Power Aur Attractive Valuation

Financials bhi improve hue hain. Net debt ab ₹1,435.8 crore hai, aur operating cash flow ₹484 crore raha 9 mahine mein (Dec 31, 2025 tak). Revenue 9MFY26 mein ₹3,535.2 crore raha, jo 4.7% zyada hai pichle saal se. EBITDA margin bhi 19.4% kaafi acha hai.

Market cap around ₹83-85 billion hai. Aur Valuation? Kafi attractive hai! P/E ratio lagbhag 16.35x hai, jabki sector ka average 58.66x hai. Socho, competitor Ajanta Pharma ka P/E 36.33x aur Gland Pharma ka 34.40x hai. Stock price March 25, 2026 ko ₹929.20 ke aas paas tha aur pichle ek saal mein stock 39.90% tak bhaga hai!

Market Position & Industry Trends

Indian pharma sector next year 7-9% grow karne ka target rakhe hue hai. Strides ka P/E ratio bhi sector average se kaafi kam hai, matlab value buying ka chance hai. Interesting baat ye hai ki pichle 5 saal mein revenue growth moderate 10.6% raha hai, but profit growth 124% CAGR raha hai – matlab margin expansion is key!

Watch Out For These Points

Haan, kuch points par dhyan dena zaroori hai. Promoter share pledging lagbhag 30.6% hai, jo thoda risky ho sakta hai. Aur debt ratio par bhi alag alag reports hain – company 1.6x bolti hai, lekin kuch analysts 6.58x tak bol rahe hain. Past mein U.S. FDA ne 2019 mein warning letter bhi diya tha quality issues par, though ab resolution dikh raha hai. ROCE bhi 7.27% comparatively kam hai.

Analysts Kya Bol Rahe Hain?

Analysts ke views mixed hain; kuch Buy bol rahe hain toh kuch Hold par. Consensus target price around ₹1,080 hai. Company ki strategy ekdam disciplined M&A par focus karne ki hai, aur debt kam karte hue sustainable profit banana hai.

Disclaimer:This content is for informational purposes only and does not constitute financial or investment advice. Readers should consult a SEBI-registered advisor before making decisions. Investments are subject to market risks, and past performance does not guarantee future results. The publisher and authors are not liable for any losses. Accuracy and completeness are not guaranteed, and views expressed may not reflect the publication’s editorial stance.